Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) Net Income towards Common Stockholders (2023 - 2026)

MBX Biosciences has reported Net Income towards Common Stockholders over the past 4 years, most recently at -$23.5 million for Q1 2026.

  • Quarterly results put Net Income towards Common Stockholders at -$23.5 million for Q1 2026, up 1.52% from a year ago — trailing twelve months through Mar 2026 was -$86.6 million (down 17.89% YoY), and the annual figure for FY2025 was -$87.0 million, down 40.45%.
  • Net Income towards Common Stockholders reached -$23.5 million in Q1 2026 per MBX's latest filing, down from -$22.1 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$8.8 million in Q4 2023 and bottomed at -$23.9 million in Q1 2025.
  • Median Net Income towards Common Stockholders over the past 4 years was -$18.1 million (2024), compared with a mean of -$17.4 million.
  • The largest annual shift saw Net Income towards Common Stockholders crashed 93.56% in 2025 before it increased 1.52% in 2026.
  • Over 4 years, Net Income towards Common Stockholders stood at -$8.8 million in 2023, then crashed by 76.25% to -$15.6 million in 2024, then tumbled by 41.55% to -$22.1 million in 2025, then dropped by 6.6% to -$23.5 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for MBX at -$23.5 million in Q1 2026, -$22.1 million in Q4 2025, and -$21.6 million in Q3 2025.